Blue Water Acquisition Corp. III (the "Company") (Nasdaq: BLUWU), a newly organized special purpose acquisition company ...

Waning fears that the Trump tariff war will scuttle the U.S. economy has been helping small cap stocks of late. Jonathan Krinsky, technical guru at BTIG, notes that the iShares Russell 200 exchange ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

Jonathan Krinsky, BTIG chief market technician, joins 'Money Movers' to discuss his bullish call for this small sector to ...

BTIG’s co-founder and executive chairman, Steven Starker, speaks to CNBC’s Contessa Brewer about the firm’s annual charity day.

The financial-services industry has tried to clean up its image in recent years, but shades of an earlier era on Wall Street have lingered at the firm BTIG, a Business Insider investigation has found.

On June 4, analysts at BTIG reiterated a Buy rating and maintained a $210 price target on Chart Industries Inc. (NYSE:GTLS).

Jim Sullivan, a managing director at BTIG who leads REIT research for the company, spoke with Commercial Observer last week to explain what went wrong for Forever 21 and how the picture is shaping up ...

Nov 13 (Reuters) - U.S. brokerage firm BTIG on Monday sued rival StoneX Group Inc (SNEX.O), opens new tab in San Francisco, accusing it of stealing trade secrets and seeking at least $200 million ...

BTIG sees increased stability for the medtech sector in 2024 as it moves past concerns about the impact of GLP-1 weight-loss drugs, supply chain snarls, and higher interest rates. “With GLP-1 ...

BTIG has decided to maintain its Buy rating of Viking Therapeutics (NASDAQ:VKTX) and raise its price target from $20.00 to $31.00. Shares of Viking Therapeutics are trading up 4.15% over the last ...